Iron chelation: A potential therapeutic strategy in oesophageal cancer

British Journal of Pharmacology

Volumn 168, Issue 6, 2013, Pages 1313-1315

  Keeler, B D ^a   Brookes, Matthew James ^b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

anti tumour agents; cell cycle; deferasirox; deferoxamine; iron chelation

Indexed keywords

2 BENZOYLPYRIDINE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; BP 44MT; DEFERASIROX; DEFEROXAMINE; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; DP 44MT; FERROPORTIN; IRON; IRON CHELATING AGENT; PYRIDOXAL ISONICOTINOYLHYDRAZONE; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CANCER THERAPY; CARCINOGENESIS; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; DIGESTIVE SYSTEM CANCER; DISEASE ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME INHIBITION; EPITHELIUM TUMOR; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRON CHELATION; IRON DEPLETION; IRON KINETICS; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; IRON TRANSPORT; LOW DRUG DOSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; WNT SIGNALING PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOATES; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HUMANS; IRON CHELATING AGENTS; TRIAZOLES;

EID: 84874424610     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12093     Document Type: Review

References (14)

1. Blatt J, Stitely S, (1987). Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res 47: 1749-1750.
2. Boult J, Roberts K, Brookes MJ, Hughes S, Bury JP, Cross SS, et al. (2008). Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Clin Cancer Res 14: 379-387.
3. Brookes MJ, Boult J, Roberts K, Cooper BT, Hotchins NA, Matthews G, et al. (2008). A role for iron in Wnt signalling. Oncogene 27: 966-975.
4. Cancer Research UK (CRUK) (2012). Oesophageal cancer statistics. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ oesophagus/ (accessed 22 October 2012).
5. Coombs GS, Schmitt AA, Canning CA, Alok A, Low ICC, Banerjee N, et al. (2012). Modulation of Wnt/b-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene 31: 213-225.
6. Ford S, Obeidy P, Lovejoy DB, Bedford M, Nichols L, Chadwick C, et al. (2012). Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. Br J Pharmacol 168: 1316-1328.
7. Kovacevic Z, Kalinowski DS, Lovejoy DB, Yu Y, Suryo Rahmanto Y, Sharpe PC, et al. (2011). The medicinal chemistry of novel iron chelators for the treatment of cancer. Curr Top Med Chem 11: 483-499.
8. Melis M, McLoughlin JM, Dean EM, Siegel EM, Weber JM, Shah N, et al. (2009). Correlations between neoadjuvant treatment, anemia, and perioperative complications in patients undergoing esophagectomy for cancer. J Surg Res 153: 114-120.
9. Muckenthaler MU, Galy B, Hentze MW, (2008). Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 28: 197-213.
10. Richardson DR, Tran EH, Ponka P, (1995). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86: 4295-4306.
11. Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, et al. (2011). Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Cancer Res 71: 7628-7639.
12. Tanswell I, Steed H, Butterworth J, Townson G, (2011). Anaemia is of prognostic significance in patients with oesophageal adenocarcinoma. J R Coll Physicians Edinb 41: 206-210.
13. Whitnall M, Howard J, Ponka P, Richardson DR, (2006). A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 103: 14901-14906.
14. Yu Y, Rahmanto YS, Richardson DR, (2012). Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br J Pharmacol 165: 148-166.